Skip to main
TLX

TLX Stock Forecast & Price Target

TLX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Telix Pharmaceuticals has demonstrated strong commercial performance, with its precision medicine segment generating $316 million in revenue during the second half of 2025, indicating solid demand driven by U.S. sales of its cancer imaging agent, Illuccix. The company reported positive top-line results for a study that could significantly expand its U.S. market footprint in prostate cancer diagnosis, presenting an additional addressable market of approximately $3.5 billion. Furthermore, Telix's ability to meet its 2025 revenue targets reflects effective execution and positions the company favorably amid high risks and notable upside opportunities in the radiopharmaceuticals sector.

Bears say

Telix Pharmaceuticals reported a net loss of $1.0 million or an earnings per share (EPS) of $(0.30), which was better than prior estimates but still highlights ongoing financial struggles amid significant operational risks. The company faces multiple challenges, including potential negative clinical outcomes with its lead therapeutic candidate, TLX591, and the possibility of delays in advancing its pipeline toward regulatory approval, which could hamper future revenue generation. Additionally, Telix is exposed to competitive pressures within the radiopharmaceutical market and faces liquidity risks that may further impact its long-term financial stability and increase dilution risk for shareholders.

TLX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Telix Pharmaceuticals Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Telix Pharmaceuticals Ltd (TLX) Forecast

Analysts have given TLX a Strong Buy based on their latest research and market trends.

According to 4 analysts, TLX has a Strong Buy consensus rating as of Apr 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Telix Pharmaceuticals Ltd (TLX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.